CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

ABSTRACT:

Background

T cells that have been modified to express a CD19-specific chimeric antigen receptor (CAR) have antitumor activity in B cell malignancies; however, identification of the factors that determine toxicity and efficacy of these T cells has been challenging in prior studies in which phenotypically heterogeneous CAR-T cell products were prepared from unselected T cells.

Methods

We conducted a clinical trial to evaluate CD19 CAR-T cells that were manufactured from defined CD4+ and CD8+ T cell subsets and administered in a defined CD4+:CD8+ composition to adults with B cell acute lymphoblastic leukemia after lymphodepletion chemotherapy.

Results

The defined composition product was remarkably potent, as 27 of 29 patients (93%) achieved BM remission, as determined by

SUBMITTER: Turtle CJ 

PROVIDER: S-EPMC4887159 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature